Vanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation

Vanda Pharmaceuticals Inc. (Vanda)

today announced that a favorable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by Vanda against Roxane Laboratories Inc. (Roxane) regarding Roxane's submission of an Abbreviated New Drug Application to make and sell a generic version of Fanapt®. A Markman ruling, also known as a Claim Construction Ruling, is a court ruling in which the judge determines the meaning of key terms from certain disputed patent claims. The Delaware court, which was asked to construe disputed patent claim terms in U.S. Patent number 8,586,610 ('610), rejected Roxane's proposed construction of all the disputed claim terms. The '610 patent is expected to expire in November 2027.